Full history for every metric is available with a Kvantra account
Lipum AB (publ) (LIPUM.ST)
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | SEK m | -63 | -64 | |||||
| Net profit | SEK m | -21 | -52 | -38 | -37 | -56 | -72 | -72 |
| EPS reported | SEK | -3.37 | -3.36 | |||||
| Operating cashflow per share | SEK | -1.65 | -1.06 | |||||
| Capex per share | SEK | 1.65 | 0.33 | |||||
| FCF per share | SEK | -1.65 | -1.06 | |||||
| Free cash flow | SEK m | -35 | -23 | |||||
| Net debt | SEK m | -2 | -2 | |||||
| Book value equity | SEK m | -5 | -5 | |||||
| Book value per share | SEK | -0.22 | -0.22 | |||||
| Number of shares | m | 21.21 | 21.21 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -65.31 | -64.19 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -8.86 | -13.48 | |||||
| EV/EBITDA LTM | x | -4.93 | -4.69 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -23.10% | -23.50% | |||||
| FCF Yield | % | -11.28% | -7.42% | |||||
| Quality | ||||||||
| ROE | % | 1508.4% | 641.22% | |||||
| ROIC | % | 1318.4% | 1357.7% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.02 | 0.02 | |||||
| EBIT/Net interest | x | -21.18 | -21.81 | |||||
| Net debt/market cap | % | -0.50% | -0.51% | |||||
| Net debt/Equity | x | 0.33 | 0.33 | |||||
| Gross debt/equity | x | -0.00 | -0.00 | |||||
Company overview
Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on pioneering the discovery and development of therapeutic solutions for long-term inflammatory conditions. The company's primary therapeutic asset, SOL-116, is a humanized antibody currently in the late preclinical stage, designed to treat pediatric rheumatism and adult rheumatoid arthritis. To facilitate the advancement of SOL-116 into clinical trials, Lipum has established a collaboration with Pelago Bioscience AB to meticulously monitor drug targets. Founded in 2010, the company's operations are headquartered in Umeå, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lipum AB (publ) (LIPUM.ST)
Lipum AB (publ) is a biopharmaceutical firm based in Sweden, focused on pioneering the discovery and development of therapeutic solutions for long-term inflammatory conditions. The company's primary therapeutic asset, SOL-116, is a humanized antibody currently in the late preclinical stage, designed to treat pediatric rheumatism and adult rheumatoid arthritis. To facilitate the advancement of SOL-116 into clinical trials, Lipum has established a collaboration with Pelago Bioscience AB to meticulously monitor drug targets. Founded in 2010, the company's operations are headquartered in Umeå, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free